CUSIP: 67001K202
Q2 2018 13F Holders as of 30 Jun 2018
-
Type / Class
-
Equity / COM NEW
-
Total 13F shares
-
14,571,400
-
Share change
-
-592,464
-
Total reported value
-
$53,623,312
-
Price per share
-
$3.68
-
Number of holders
-
46
-
Value change
-
-$2,024,604
-
Number of buys
-
13
-
Number of sells
-
34
Quarterly Holders Quick Answers
What is CUSIP 67001K202?
CUSIP 67001K202 identifies NVLNF - NOVELION THERAPEUTICS INC - COM NEW in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
-
Newer quarter:
Q3 2018
-
Previous quarter:
Q1 2018
Recent filing periods for CUSIP 67001K202:
Institutional Holders of NOVELION THERAPEUTICS INC - COM NEW (NVLNF) as of Q2 2018
As of 30 Jun 2018,
NOVELION THERAPEUTICS INC - COM NEW (NVLNF) was held by
46 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
14,571,400 shares.
The largest 10 holders included
EdgePoint Investment Group Inc., Broadfin Capital, LLC, ARMISTICE CAPITAL, LLC, Stonepine Capital Management, LLC, MORGAN STANLEY, Healthcare Value Capital, LLC, Sarissa Capital Management LP, FMR LLC, MILLENNIUM MANAGEMENT LLC, and JW Asset Management, LLC.
This page lists
46
institutional shareholders reporting positions in this security
for the Q2 2018 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.